ARTICLE | Financial News

Selecta raises $38M in series E

September 9, 2015 1:12 AM UTC

Selecta Biosciences Inc. (Watertown, Mass.) raised $38 million in a series E round led by existing investor OrbiMed. New investors Sanofi Genzyme Bioventures; Ridgeback Capital Management; Osage Partners; Aju IB Investment; and Sphera Global Health Care Fund participated, as did existing investors Polaris Venture Partners; Flagship Ventures; NanoDimension; Rusnano; and Leukon Investments.

Selecta's SEL-212 is in a Phase I study to treat refractory and tophaceous gout. The company plans to begin a Phase II trial in the same indication next year, and expects data in mid-2016. The company has exclusive, worldwide rights excluding Japan, China and Taiwan from 3SBio Inc. (HKSE:1530) to the non-immunogenic version of pegsiticase utilizing the Synthetic Vaccine Particle (SVP) platform. ...